Reuters logo
BRIEF-Biohaven receives FDA may proceed letter for phase 2/3 clinical trial of Trigriluzole
October 24, 2017 / 7:14 AM / 2 months ago

BRIEF-Biohaven receives FDA may proceed letter for phase 2/3 clinical trial of Trigriluzole

Oct 24 (Reuters) - Biohaven Pharmaceutical Holding Company Ltd

* Biohaven receives FDA may proceed letter for phase 2/3 clinical trial of Trigriluzole in patients with obsessive-compulsive disorder

* U.S. Food and drug administration (FDA) has notified co that it may proceed with its clinical investigation of Trigriluzole​

* Expects to commence a phase 2/3 clinical trial of Trigriluzole in OCD in the current quarter

* ‍expects to report topline results in Q1 of 2018 for acute treatment of migraine​

* Data from long-term safety study is expected to support a potential NDA submission in first half of 2019​

* ‍Also expects to file an IND with FDA by end of this year for BHV-3500 for treatment of migraine​

* Anticipates commencing bioequivalence study for bhv-0223 for treatment of patients with ALS in Q4 Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below